Quantitative mapping shows that serotonin rather than dopamine receptor mRNA expressions are affected after repeated intermittent administration of MDMA in rat brain

Neuropharmacology

Volumn 51, Issue 4, 2006, Pages 838-847

  Kindlundh Högberg, Anna M S ^a,b   Svenningsson, Per ^a   Schiöth, Helgi B ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Dopamine receptor; Drug abuse; Ecstasy; MDMA; mRNA; Serotonin receptor

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; MESSENGER RNA; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 6 RECEPTOR;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN NUCLEUS; CAUDATE NUCLEUS; CONTROLLED STUDY; FOREBRAIN; GENE EXPRESSION; HYPOTHALAMUS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION; HALLUCINOGENS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 33747816496     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.05.026     Document Type: Article

References (78)

1. Aguirre N., Frechilla D., Garcia-Osta A., Lasheras B., and Del Rio J. Differential regulation by methylenedioxymethamphetamine of 5-hydroxytryptamine1A receptor density and mRNA expression in rat hippocampus, frontal cortex, and brainstem: the role of corticosteroids. J. Neurochem. 68 (1997) 1099-1105
2. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
3. Battaglia G., Yeh S.Y., and De Souza E.B. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 29 (1988) 269-274
4. Battaglia G., Sharkey J., Kuhar M.J., and de Souza E.B. Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography. Synapse 8 (1991) 249-260
5. Berridge K.C., and Robinson T.E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?. Brain Res. Brain Res. Rev. 28 (1998) 309-369
6. Bickerdike M.J., Vickers S.P., and Dourish C.T. 5-HT2C receptor modulation and the treatment of obesity. Diabetes Obes. Metab. 1 (1999) 207-214
7. Check E. Psychedelic drugs: the ups and downs of ecstasy. Nature 429 (2004) 126-128
8. Cohen R.S. Subjective reports on the effects of the MDMA ("ecstasy") experience in humans. Prog. Neuropsychopharmacol. Biol. Psychiatry 19 (1995) 1137-1145
9. Cohen J.D., Braver T.S., and O'Reilly R.C. A computational approach to prefrontal cortex, cognitive control and schizophrenia: recent developments and current challenges. Philos. Trans. R. Soc. Lond. B Biol. Sci. 351 (1996) 1515-1527
10. Cole J.C., and Sumnall H.R. Altered states: the clinical effects of Ecstasy. Pharmacol. Ther. 98 (2003) 35-58
11. Curran H.V., Rees H., Hoare T., Hoshi R., and Bond A. Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users. Psychopharmacology (Berl.) 173 (2004) 425-433
12. Dafters R.I. Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol. Behav. 58 (1995) 877-882
13. De Deurwaerdere P., and Spampinato U. Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J. Neurochem. 73 (1999) 1033-1042
14. Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. Eur. J. Pharmacol. 375 (1999) 13-30
15. Di Chiara G., Tanda G., Bassareo V., Pontieri F., Acquas E., Fenu S., Cadoni C., and Carboni E. Drug addiction as a disorder of associative learning. Role of nucleus accumbens shell/extended amygdala dopamine. Ann. N.Y. Acad. Sci. 877 (1999) 461-485
16. Di Matteo V., De Blasi A., Di Giulio C., and Esposito E. Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol. Sci. 22 (2001) 229-232
17. Everitt B.J., Parkinson J.A., Olmstead M.C., Arroyo M., Robledo P., and Robbins T.W. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann. N.Y. Acad. Sci. 877 (1999) 412-438
18. Fetissov S.O., Meguid M.M., Sato T., and Zhang L.H. Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283 (2002) R905-R910
19. Fone K.C., Beckett S.R., Topham I.A., Swettenham J., Ball M., and Maddocks L. Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology (Berl.) 159 (2002) 437-444
20. Geyer M.A. Serotonergic functions in arousal and motor activity. Behav. Brain Res. 73 (1996) 31-35
21. Gold L.H., and Koob G.F. MDMA produces stimulant-like conditioned locomotor activity. Psychopharmacology (Berl.) 99 (1989) 352-356
22. Goldstein R.Z., and Volkow N.D. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry 159 (2002) 1642-1652
23. Gouzoulis-Mayfrank E., Fischermann T., Rezk M., Thimm B., Hensen G., and Daumann J. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use. Drug Alcohol Depend. 78 (2005) 317-323
24. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55 (2003) 463-508
25. Gurtman C.G., Morley K.C., Li K.M., Hunt G.E., and McGregor I.S. Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. Eur. J. Pharmacol. 446 (2002) 89-96
26. Hermansson, G., 2005. National Criminal Investigation Service Rikskriminalpolisen, Stockholm.
27. Iravani M.M., Jackson M.J., Kuoppamaki M., Smith L.A., and Jenner P. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J. Neurosci. 23 (2003) 9107-9115
28. Jentsch J.D., and Taylor J.R. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl.) 146 (1999) 373-390
29. Kalivas P.W., Duffy P., and White S.R. MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology 18 (1998) 469-479
30. Kaufman J.N., Ross T.J., Stein E.A., and Garavan H. Cingulate hypoactivity in cocaine users during a GO-NOGO task as revealed by event-related functional magnetic resonance imaging. J. Neurosci. 23 (2003) 7839-7843
31. Kelley A.E. Neural integrative activities of nucleus accumbens subregions in relation to motivation and learning. Psychobiology 27 (1999) 198-213
32. Kelley A.E., and Berridge K.C. The neuroscience of natural rewards: relevance to addictive drugs. J. Neurosci. 22 (2002) 3306-3311
33. Kelley A.E., Schiltz C.A., and Landry C.F. Neural systems recruited by drug- and food-related cues: Studies of gene activation in corticolimbic regions. Physiol. Behav. 86 (2005) 11-14
34. Kindlundh A.M., Isacson D.G., Berglund L., and Nyberg F. Factors associated with adolescent use of doping agents: anabolic- androgenic steroids. Addiction 94 (1999) 543-553
35. af Klinteberg B., Hallman J., Oreland L., Wirsen A., Levander S.E., and Schalling D. Exploring the connections between platelet monoamine oxidase activity and behavior. II. Impulsive personality without neuropsychological signs of disinhibition in air force pilot recruits. Neuropsychobiology 26 (1992) 136-145
36. Krugel U., Schraft T., Kittner H., Kiess W., and Illes P. Basal and feeding-evoked dopamine release in the rat nucleus accumbens is depressed by leptin. Eur. J. Pharmacol. 482 (2003) 185-187
37. Lee M.D., Kennett G.A., Dourish C.T., and Clifton P.G. 5-HT1B receptors modulate components of satiety in the rat: behavioural and pharmacological analyses of the selective serotonin1B agonist CP-94,253. Psychopharmacology (Berl.) 164 (2002) 49-60
38. Leibowitz S.F., and Alexander J.T. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol. Psychiatry 44 (1998) 851-864
39. Lindblom J., Haitina T., Fredriksson R., and Schioth H.B. Differential regulation of nuclear receptors, neuropeptides and peptide hormones in the hypothalamus and pituitary of food restricted rats. Brain Res. Mol. Brain Res. 133 (2005) 37-46
40. Linnoila M., Virkkunen M., Scheinin M., Nuutila A., Rimon R., and Goodwin F.K. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci. 33 (1983) 2609-2614
41. McCann U.D., Ridenour A., Shaham Y., and Ricaurte G.A. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 10 (1994) 129-138
42. McCann U.D., Mertl M., Eligulashvili V., and Ricaurte G.A. Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology (Berl.) 143 (1999) 417-425
43. McCann U.D., Szabo Z., Seckin E., Rosenblatt P., Mathews W.B., Ravert H.T., Dannals R.F., and Ricaurte G.A. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [(11)C]McN5652 and [(11)C]DASB. Neuropsychopharmacology 30 (2005) 1741-1750
44. McCardle K., Luebbers S., Carter J.D., Croft R.J., and Stough C. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berl.) 173 (2004) 434-439
45. McCreary A.C., Bankson M.G., and Cunningham K.A. Pharmacological studies of the acute and chronic effects of (±)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors. J. Pharmacol. Exp. Ther. 290 (1999) 965-973
46. McGregor I.S., Clemens K.J., Van der Plasse G., Li K.M., Hunt G.E., Chen F., and Lawrence A.J. Increased anxiety 3 months after brief exposure to MDMA ("Ecstasy") in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 28 (2003) 1472-1484
47. Mordenti J., and Chappell W. The use of interspecies scaling in toxicokinetics. In: Yacogi A., Kelly J., and Batra V. (Eds). Toxicokinetics and New Drug Development (1989), Pergamon Press, New York 42-96
48. Morgan M.J. Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 19 (1998) 252-264
49. Morley K.C., Gallate J.E., Hunt G.E., Mallet P.E., and McGregor I.S. Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy"). Eur. J. Pharmacol. 433 (2001) 91-99
50. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr. Opin. Pharmacol. 5 (2005) 79-86
51. O'Shea E., Granados R., Esteban B., Colado M.I., and Green A.R. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ("ecstasy"). Neuropharmacology 37 (1998) 919-926
52. Parrott A.C. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol. Biochem. Behav. 71 (2002) 837-844
53. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1997), Academic Press, San Diego
54. Petrovich G.D., Canteras N.S., and Swanson L.W. Combinatorial amygdalar inputs to hippocampal domains and hypothalamic behavior systems. Brain Res. Brain Res. Rev. 38 (2001) 247-289
55. Piper B.J., and Meyer J.S. Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol. Biochem. Behav. 79 (2004) 723-731
56. Pittenger C., and Kandel E. A genetic switch for long-term memory. C.R. Acad. Sci. III 321 (1998) 91-96
57. Pontieri F.E., Tanda G., and Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc. Natl. Acad. Sci. USA 92 (1995) 12304-12308
58. Reneman L., Endert E., de Bruin K., Lavalaye J., Feenstra M.G., de Wolff F.A., and Booij J. The acute and chronic effects of MDMA ("ecstasy") on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 26 (2002) 387-396
59. Robinson T.E., and Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Brain Res. Rev. 18 (1993) 247-291
60. Sato T., Meguid M.M., Fetissov S.O., Chen C., and Zhang L. Hypothalamic dopaminergic receptor expressions in anorexia of tumor-bearing rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281 (2001) R1907-R1916
61. Scearce-Levie K., Viswanathan S.S., and Hen R. Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor. Psychopharmacology (Berl.) 141 (1999) 154-161
62. Schmidt W.J., Mayerhofer A., Meyer A., and Kovar K.A. Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?. Neurosci. Lett. 330 (2002) 251-254
63. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 80 (1998) 1-27
64. Simansky K.J. Serotonergic control of the organization of feeding and satiety. Behav. Brain Res. 73 (1996) 37-42
65. Spanos L.J., and Yamamoto B.K. Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol. Biochem. Behav. 32 (1989) 835-840
66. Stone D.M., Stahl D.C., Hanson G.R., and Gibb J.W. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur. J. Pharmacol. 128 (1986) 41-48
67. Stone D.M., Merchant K.M., Hanson G.R., and Gibb J.W. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26 (1987) 1677-1683
68. Swanson L.W. Cerebral hemisphere regulation of motivated behavior. Brain Res. 886 (2000) 113-164
69. Taylor J.R., and Jentsch J.D. Repeated intermittent administration of psychomotor stimulant drugs alters the acquisition of Pavlovian approach behavior in rats: differential effects of cocaine, d-amphetamine and 3,4-methylenedioxymethamphetamine ("Ecstasy"). Biol. Psychiatry 50 (2001) 137-143
70. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., and Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3 (2002) RESEARCH0034
71. Verkes R.J., Gijsman H.J., Pieters M.S., Schoemaker R.C., de Visser S., Kuijpers M., Pennings E.J., de Bruin D., Van de Wijngaart G., Van Gerven J.M., and Cohen A.F. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology (Berl.) 153 (2001) 196-202
72. Wang G.J., Volkow N.D., Logan J., Pappas N.R., Wong C.T., Zhu W., Netusil N., and Fowler J.S. Brain dopamine and obesity. Lancet 357 (2001) 354-357
73. Winstanley C.A., Dalley J.W., Theobald D.E., and Robbins T.W. Fractionating impulsivity: contrasting effects of central 5-HT depletion on different measures of impulsive behavior. Neuropsychopharmacology 29 (2004) 1331-1343
74. Winstanley C.A., Theobald D.E., Dalley J.W., Glennon J.C., and Robbins T.W. 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology (Berl.) 176 (2004) 376-385
75. Volkow N.D., and Fowler J.S. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb. Cortex 10 (2000) 318-325
76. von Knorring L., Oreland L., and Winblad B. Personality traits related to monoamine oxidase activity in platelets. Psychiatry Res. 12 (1984) 11-26
77. Yau J.L., Kelly P.A., Sharkey J., and Seckl J.R. Chronic 3,4-methylenedioxymethamphetamine administration decreases glucocorticoid and mineralocorticoid receptor, but increases 5-hydroxytryptamine1C receptor gene expression in the rat hippocampus. Neuroscience 61 (1994) 31-40
78. Yau J.L., Noble J., and Seckl J.R. Site-specific regulation of corticosteroid and serotonin receptor subtype gene expression in the rat hippocampus following 3,4-methylenedioxymethamphetamine: role of corticosterone and serotonin. Neuroscience 78 (1997) 111-121